Clinical trials: First Pregnancy
Pregnancy Early
Assessing Gestational Age in First Trimester Pregnancies Using Ultrasound
The objective of this study is to assess equivalency of the transabdominal Clarius handheld wifi C3 ultrasound (which uses Bluetooth to locate the ipad Mini 5 and then uses wifi direct to show the images) to the current standard…
- Trial name
- NCT03957200
- Where
- 2 sites in Canada
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Preterm Birth, Low Birth Weight
Description and Comparison of Biological Vulnerability in Small Vulnerable Newborns Versus Healthy Community Controls in Urban Burkina Faso
The aim of the DenBalo study is to apply integrated multi-omics methods to examine the biological mechanisms underlying this vulnerability in Small Vulnerable Newborns (SVNs) in LMICs, with the ultimate goal of identifying…
- Conditions
- Preterm Birth, Low Birth Weight, Small for Gestational Age at Delivery
- Trial name
- DenBalo (NCT05730569)
- Where
- Burkina Faso
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University Ghent
Ovarian Cancer
A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer
This single arm study evaluated the efficacy and safety of first-line chemotherapy with carboplatin and dose-dense weekly paclitaxel plus bevacizumab (Avastin) in participants with epithelial ovarian, fallopian tube, or primary…
- Trial name
- NCT00937560
- Testing
- Bevacizumab, Paclitaxel, Carboplatin
- Where
- 55 sites in Brazil, France and 7 more
- Volunteers
- 190 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer, Fallopian Tube Cancer
Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Primary Objective: 1. Evaluate the efficacy of letrozole to increase the duration of progression-free survival (defined as time to earliest occurrence of local or distant recurrence or clinically significant elevation in CA-125)…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT00634894
- Testing
- Femara
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer
Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer
The goal of this clinical research study is to see if ovarian cancer patients who add Juice PLus+ and Juice Plus+ Complete to their diets have better outcomes when compared to ovarian cancer patients who receive only dietary…
- Trial name
- NCT01439659
- Testing
- Nutritional Counseling, Daily Supplements
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- M.D. Anderson Cancer Center
Allergy
Influence of Probiotic VSL#3 Administration on Metabolic and Immunological Profile of the Milk of Breastfeeding Mothers
The newborn immune system is influenced by maternal immunity through both placenta and breastfeeding. There exists a close interaction between the mother and the baby during gestation and lactation.
- Trial name
- NCT01367470
- Testing
- VSL#3 probiotic preparation
- Where
- 2 sites in Italy
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Policlinico Hospital
Woman's Role, Preeclampsia
Women's Perspective on First-trimester Preeclampsia Screening
The aim of this study is to evaluate women's perception on first-trimester preeclampsia screening as it is performed currently in daily practice.
- Conditions
- Woman's Role, Preeclampsia, Screening
- Trial name
- NCT05123560
- Testing
- Anonymous online questionnaire
- Where
- Spain
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Recurrent Bladder Carcinoma, Bladder Cancer Stage 0
sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer
This phase I trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein (sEphB4-HSA), and to see how well it works in treating participants with bladder cancer that has come back or that isn't responding…
- Conditions
- Recurrent Bladder Carcinoma, Bladder Cancer Stage 0, Bladder Cancer Stage I
- Trial name
- NCT03552796
- Testing
- Pharmacokinetic Study, Recombinant EphB4-HSA Fusion Protein
- Where
- United States
- Sponsor
- University of Southern California
Pregnancy
Median Study for Biochemical Serum Markers in First Trimester of Pregnancy
The purpose of this study is to get initial values (normal medians) for certain biochemical serum markers for pregnancy weeks 10-13.
- Trial name
- NCT01891370
- Where
- 3 sites in Malaysia, Philippines and 1 more
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- PerkinElmer, Wallac Oy
Fallopian Tube Cancer, Ovarian Cancer
Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sometimes after treatment, the tumor may not need additional treatment until it progresses.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00263822
- Testing
- erlotinib hydrochloride
- Where
- 92 sites in Australia, Austria and 6 more
- Volunteers
- 835 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
RCC, Renal Cell Cancer
Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy
The primary objective is to evaluate the improvement in Objective Response Rate (ORR) achieved with Iparomlimab and Tuvonralimab Injection (QL1706, an Anti-PD-1/CTLA-4 Combined Antibody) in combination with Lenvatinib or…
- Trial name
- NCT07277972
- Testing
- Iparomlimab and Tuvonralimab Injection in combination with Lenvatinib or Axitinib
- Volunteers
- 36 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer
EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma
MDG1015 is a third generation TCR-T therapy product targeting NY-ESO-1/LAGE-1a armored and enhanced by the PD1-41BB costimulatory switch protein (CSP).
- Conditions
- Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma
- Trial name
- EPITOME-1015-I (NCT06748872)
- Testing
- Lymphodepletion, TCR-T cells (MDG1015)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Medigene AG
Carcinoma, Renal Cell
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in…
- Trial name
- NCT04736706
- Testing
- Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab
- Where
- 262 sites in United States, Australia and 33 more
- Volunteers
- 1,688 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Cancer
A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
This is a Prospective,Single-Center, Single-Arm, Phase 2 study to evaluate the efficacy and safety of Fluzoparib Combined With QL1101, as maintenance treatment, in patients with Advanced FIGO Stage III or IV High Grade Serous or…
- Trial name
- NCT05585281
- Testing
- Fluzoparib, QL1101
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Yongpeng Wang
Prematurity, Nutrition
Nutritional Content of Breast Milk From Mothers of Premies
The purpose of this study is to determine the correlation, if any, between the nutritional content of breast milk pumped by the mothers of very low birth weight (VLBW) infants in the neonatal intensive care unit (NICU) and the…
- Trial name
- NCT01050192
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pediatrix
Ovarian Cancer, HGSOC
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian, fallopian tube, or primary peritoneal cancer, collectively referred to as ovarian cancer, remains the deadliest type of gynaecological cancer.
- Conditions
- Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Trial name
- OVACT (NCT07665515)
- Testing
- CryptiVax-1001
- Where
- 10 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Epitopea Ltd
Induced Abortion
Is Oxytocin Given During Surgical Procedure for Abortion Before 12 Weeks of Pregnancy Useful?
This is a randomized, single-blind study using oxytocin 5U i.v. during surgical abortion in one arm of the study, and no medication in the other arm of the study.
- Trial name
- oxystudien (NCT00540748)
- Testing
- oxytocin
- Where
- Norway
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Asker & Baerum Hospital
Labor Stage, First, Prolonged Labor
Maternal Maneuvers During Prolonged Labor
This pilot, randomized control trial will test whether or not a specific circuit of position changes improves maternal outcomes in cases of prolonged labor.
- Trial name
- CIRCUIT (NCT06636149)
- Testing
- Circuit of maternal position changes during labor
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Washington University School of Medicine
Recurrent Ovarian Cancer
Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer
Bevacizumab has been found to prolong progression free survival in first line, and more recently, in second line treatment for platinum sensitive ovarian cancer patients who had not received prior treatment with bevacizumab.
- Trial name
- MITO16MANGO2b (NCT01802749)
- Testing
- Bevacizumab, Paclitaxel, Carboplatin
- Where
- 82 sites in France, Greece and 3 more
- Volunteers
- 406 people
- Sponsor
- National Cancer Institute, Naples
Missed Abortion
Sublingual Versus Vaginal Misoprostol In Medical Treatment of First Trimestric Missed Miscarriage
The aim of this work is to compare the effectiveness of vaginal versus sub-lingual misoprostol for medical treatment of first trimester missed miscarriage.
- Trial name
- NCT02686840
- Testing
- sublingual misoprostol, vaginal misoprostol
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Ain Shams University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.